EWPI (Emerging World Pharma) EBITDA Margin %: 0.00% (As of . 20)


What is Emerging World Pharma EBITDA Margin %?

Emerging World Pharma EWPI -98.00% EBITDA Margin % is 0.00% as of . 20.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Emerging World Pharma's EBITDA for the three months ended in . 20 was $0.00 Mil. Emerging World Pharma's Revenue for the three months ended in . 20 was $0.00 Mil. Therefore, Emerging World Pharma's EBITDA margin for the quarter that ended in . 20 was 0.00%.

Emerging World Pharma  (OTCPK:EWPI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Emerging World Pharma EBITDA Margin % Related Terms

Emerging World Pharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Emerging World Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emerging World Pharma EBITDA Margin % Chart

Emerging World Pharma Annual Data
Trend
EBITDA Margin %

Emerging World Pharma Quarterly Data
EBITDA Margin %

EWPI vs ENZB, AOXG: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emerging World Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emerging World Pharma EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emerging World Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Emerging World Pharma's EBITDA Margin % falls into.


Emerging World Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Emerging World Pharma's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

Emerging World Pharma's EBITDA Margin % for the quarter that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Emerging World Pharma (EWPI) has a EBITDA Margin % of 0.00% as of . 20. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Emerging World Pharma and its competitors.
Is Emerging World Pharma's EBITDA Margin % too high?
Emerging World Pharma's current EBITDA Margin % is 0.00%.
How does Emerging World Pharma's EBITDA Margin % compare to ENZB and AOXG?
Emerging World Pharma's EBITDA Margin % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Emerging World Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emerging World Pharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emerging World Pharma stock overvalued right now?
Emerging World Pharma (EWPI) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Emerging World Pharma (EWPI), the current EBITDA Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emerging World Pharma Business Description

Address Block 11A, Pastoral Road, Sunyani, GHA, 20109
Emerging World Pharma Inc is an investor in generic based pharmaceutical companies manufacturing within developing nations.